$AVXL News

Aevex stock drops 5% as US Navy halts $130M drone boat program

Anavex Provides Corporate Update, Announces Completion of Clinical Conduct of ADME and DDI Clinical Studies

Anavex Life Sciences Completes Clinical Conduct Of Drug-Drug Interaction, Absorption, Distribution, Metabolism And Excretion Trials Of Blarcamesine; Receives FDA Clearance For Its Investigational New Drug Application In Fragile X Syndrome; To Meet With FDA To Discuss Inclusion Of Participants In Its Phase 3 Rett Syndrome Trial

Anavex: Downgrading To Sell On Blarcamesine MAA Withdrawal For AD, Pipeline Change

Anavex Receives FDA IND Clearance for Blarcamesine in Fragile X Syndrome, Enabling Phase 2a Trial

Anavex Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X Syndrome

Anavex Life Sciences Receives FDA Clearance to Proceed Ahead With Its Planned Clinical Trial Under Its Investigational New Drug Application For ANAVEX 2-73 For Fragile X Syndrome

Anavex Stockholders Elect All of the Company’s Director Nominees at 2026 Annual Meeting

PVG Asset Management Announces Plan for First 100 Days at Anavex Life Sciences

Glass Lewis Recommends Anavex Stockholders Vote the GOLD Universal Proxy Card, Citing “Functionally Inert Stewardship” in Support of PVG Asset Management’s Call for Change

Anavex Life Sciences Corp. (AVXL) Discusses Board Misalignment, Leadership Concerns, and Strategic Changes for Company Turnaround Transcript

PVG Asset Management Believes ISS Acknowledges Anavex’s Repeated Missteps, Failed Board Oversight, Lack of Director Stock Ownership, and AVXL Stock Price Underperformance

Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex’s Highly Qualified Director Nominees

PVG Asset Management to Host Investor Call Regarding Anavex Life Sciences Proxy Campaign

Anavex Life Sciences Corp. (AVXL) Discusses Clinical Development Strategy and Path Forward for CNS Indications Prepared Remarks Transcript

PVG Asset Management Issues Important Information About Anavex Life Sciences (AVXL)

Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET

PVG Sends Open Letter to Anavex Stockholders Detailing the Need for Change at the Company

Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement

Anavex Life Sciences Regains Nasdaq Compliance